Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
2024年5月23日 - 5:15AM
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery
and development stage specialty pharmaceutical company focused on
improving the outcomes of cancer patients treated with radiation
therapy (RT), today announced that Dr. Anatoly Dritschilo, Chief
Executive Officer, will participate in a webcasted presentation and
host one-on-one meetings with investors at the Lytham Partners
Spring 2024 Investor Conference, taking place virtually on
Thursday, May 30, 2024.
Dr. Dritschilo’s presentation will include an update on the
Company's progress toward clinical and scientific milestones of its
Phase 2 Clinical Trial of Ropidoxuridine for treatment of patients
with glioblastoma, a deadly malignancy of the brain with no known
cure. Additionally, he will provide an update on the Company’s
plans of its subsidiary, Shuttle Diagnostics, Inc., to develop
predictive biomarkers for prostate cancer outcomes following
radiation therapy, and novel PSMA ligand for theranostic
applications.
Company Webcast
The webcasted presentation will take place at 11:00 am ET on
Thursday, May 30, 2024. The webcast can be accessed by visiting the
conference home page at https://lythampartners.com/spring2024/ or
directly at https://wsw.com/webcast/lytham11/shph/2100483. The
webcast will also be available for replay following the event.
1×1 Meetings
Management will be participating in virtual one-on-one meetings
throughout the event. To arrange a meeting with management, please
contact Lytham Partners at 1×1@lythampartners.com or register for
the event at https://lythampartners.com/spring2024invreg/.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown
University Medical Center, Shuttle Pharmaceuticals is a
discovery and development stage specialty pharmaceutical company
focused on improving the outcomes for cancer patients treated with
radiation therapy (RT). Our mission is to improve the lives of
cancer patients by developing therapies that are designed to
maximize the effectiveness of RT while limiting the side effects of
radiation in cancer treatment. Although RT is a proven modality for
treating cancers, by developing radiation sensitizers, we aim to
increase cancer cure rates, prolong patient survival and improve
quality of life when used as a primary treatment or in combination
with surgery, chemotherapy and immunotherapy. For more information,
please visit our website at www.shuttlepharma.com.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO240-403-4212
info@shuttlepharma.com
Investor ContactsLytham Partners, LLCRobert
Blum 602-889-9700shph@lythampartners.com
Shuttle Pharmaceuticals (NASDAQ:SHPH)
過去 株価チャート
から 5 2024 まで 6 2024
Shuttle Pharmaceuticals (NASDAQ:SHPH)
過去 株価チャート
から 6 2023 まで 6 2024